• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pascal Soriot and Judy Gawlik Brown Named to Agilent Board of Directors

    5/21/25 8:30:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Global life-sciences and financial leaders bring decades of health-care, biopharma, and strategic expertise to support Agilent's next phase of growth

    Agilent Technologies Inc. (NYSE:A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors, effective May 21, 2025.

    Soriot and Gawlik Brown bring decades of global leadership experience across the pharmaceutical, biotechnology, and health-care sectors, with proven track records in strategy, innovation, operations, and finance.

    Pascal Soriot has led AstraZeneca as CEO since 2012, guiding the company's transformation into a global leader in science-driven innovation with a strong pipeline and substantial growth. He has previously held other executive roles, including CEO of Genentech and Chief Operating Officer of Roche's pharmaceutical division. His global career has spanned leadership roles in Australia, Europe, Japan, and the U.S., and he has served on several industry boards.

    Judy Gawlik Brown is a seasoned financial and strategic adviser with deep experience across the life-sciences and consumer-health industries as both an executive and board member. Also, her career has included international postings in Germany and Italy. Through her consultancy, Downtown Advisory, she advises health-care and biotech companies on growth and strategy. She previously served as Chief Financial Officer of Perrigo Company, Senior Vice President of Finance at Amgen and subsequently Senior Vice President of Corporate Affairs; she also has held other senior-leadership roles overseeing financial and corporate-strategy functions.

    "Pascal brings decades of global pharmaceutical-industry leadership experience, which will be invaluable to Agilent at the start of our three-year Ignite Transformation," said Padraig McDonnell, Agilent president and CEO. "Judy's experience as a financial executive and as a director of several high-performing health-care organizations makes her a valuable addition to the Agilent Board as we seek to grow Agilent. We're delighted to welcome both Judy and Pascal to our Board."

    The Board couldn't be happier to welcome Judy and Pascal, said Koh Boon Hwee, chair of the Agilent Board.

    "Their experience, skills, and professionalism will strongly benefit our shareholders," he said. "This also further continues our commitment to the balanced refreshment of our Board of Directors."

    Agilent also announced that Heidi Kunz has retired from the Board of Directors, effective May 21, 2025, after more than 20 years of service. Kunz joined the Board in 2000, at the company's inception.

    "It has been an honor to serve on Agilent's Board for the past two decades," Kunz said. "I am proud of being able to help guide the evolution and growth of the company from its first days as a spun-out entity to one of the leading companies in its industry."

    McDonnell expressed gratitude for Kunz's service.

    "I can't thank Heidi enough for her decades of contributions to Agilent," he said.

    Boon Hwee referred to Kunz as "a foundational member" of the Agilent Board.

    "Heidi has made an immeasurable contribution to Agilent's success," he said. "We are deeply grateful for her leadership and long-standing service."

    About Agilent Technologies

    Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

    Follow Agilent on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250521630066/en/

    Media Contact:

    Andréa Topper

    +1 408-709-0060

    [email protected]

    Get the next $A alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Leadership Updates

    Live Leadership Updates

    See more
    • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

      Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

      4/24/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Acquire North American CDMO BIOVECTRA

      Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

      7/22/24 9:01:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agilent upgraded by Barclays with a new price target

      Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

      2/10/25 6:55:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Agilent with a new price target

      Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

      8/28/24 7:20:29 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent upgraded by Citigroup with a new price target

      Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

      7/10/24 7:22:08 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $A
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

      SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 1:27:37 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 11:54:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/4/24 10:57:57 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Announces Cash Dividend of 24.8 Cents per Share

      Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted ans

      5/21/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pascal Soriot and Judy Gawlik Brown Named to Agilent Board of Directors

      Global life-sciences and financial leaders bring decades of health-care, biopharma, and strategic expertise to support Agilent's next phase of growth Agilent Technologies Inc. (NYSE:A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors, effective May 21, 2025. Soriot and Gawlik Brown bring decades of global leadership experience across the pharmaceutical, biotechnology, and health-care sectors, with proven track records in strategy, innovation, operations, and finance. Pascal Soriot has led AstraZeneca as CEO since 2012, guiding the company's transformation into a global leader i

      5/21/25 8:30:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Announces My Green Lab Ecolabel 2.0 for the New Infinity III LC Series

      Advancing sustainable innovation in liquid chromatography Agilent Technologies Inc. (NYSE:A) today announced that the Infinity III LC Series — the company's latest liquid chromatography (LC) instruments — are the first Agilent instruments to receive the new My Green Lab® ACT® Ecolabel 2.0, further reinforcing Agilent's commitment to sustainable scientific innovation. Designed for efficiency, upgradeability, and environmental responsibility, the Infinity III LC Series offers laboratories a forward-thinking approach to liquid chromatography. The influence of sustainability on how science is done continues to grow, as individuals, institutions, and government agencies globally embrace more r

      5/20/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Soriot Pascal was granted 1,677 shares (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/23/25 10:39:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • New insider Soriot Pascal claimed no ownership of stock in the company (SEC Form 3)

      3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/23/25 10:37:37 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Brown Judy L was granted 1,677 shares (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/23/25 10:35:55 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Announces Cash Dividend of 24.8 Cents per Share

      Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted ans

      5/21/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

      Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag

      4/16/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Reports First-Quarter Fiscal Year 2025 Financial Results

      Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core(1) basis compared with the first quarter of 2024. GAAP net income of $318 million; earnings per share (EPS) of $1.11, down 6% from the first quarter of 2024. Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2% from the first quarter of 2024. Outlook for full 2025 fiscal year and Q2 Full-year revenue outlook is now in the range of $6.68 billion to $6.76 billion, representing a range of up 2.6% to 3.8% reported and 2.5% to 3.5% core(1).

      2/26/25 4:04:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    SEC Filings

    See more
    • Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      5/21/25 9:00:10 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 8-K filed by Agilent Technologies Inc.

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      5/2/25 4:01:23 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      4/2/25 4:58:34 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Gonsalves Rodney (Amendment)

      4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      10/20/23 1:07:25 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      9/29/23 4:03:46 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials